K-924 Phase III Long Term Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT04289662
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 110 participants
- Sponsor
- Registry
-
NCT04289662
-
- Other papers using this trial's data
- Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT04289662. Non-randomized; no masking; primary purpose treatment. Start 2020-03-23 (actual); primary completion 2021-08-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- K-924 Phase III Long Term Study
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- K-924 LD
- Intervention (Drug)
- K-924 HD
- Lead sponsor
- Kowa Company, Ltd.
Record details
- Record id
cardio:ct-nct04289662- Content hash
40d75a7e0bb492b9f807e1f4c0679f8f43dd40953c835a8b6e38b7453608d00f